Goldman Sachs questions whether curing patients is a sustainable business model

Re:Goldman Sachs questions whether curing patients is a sust... by davemel37 on Friday April 13, 2018 @12:55PM (#16831746)

The problem here is not business interests its the IP protections that keep the pressure from being applied by the marketplace.

I dont know enough to have an educated opinion on healthcare regulation or on social services...but its disengenuous to claim that medicine cant be managed as a business when its already so heavily regulated that it barely looks like a normal business.

I would agree that the current model is super messed up...but maybe managing it like a business without all the government intervention and IP laws is the better solution here... maybe not...i dont know...but you definitely cant support your conclusion from the current environment.

[ Parent | on HN ]

Re:Goldman Sachs questions whether curing patients is a sust... by orbitingpluto on Friday April 13, 2018 @01:10PM (#16831880)

Great argument. Would you like to buy some ED medication I made by stuffing capsules with Drano? /s

[ Parent | on HN ]

Re:Goldman Sachs questions whether curing patients is a sust... by davemel37 on Sunday April 15, 2018 @12:21PM (#16843323)

No ones talking about drug approvals...im talking about IP protections after its approved... do you have any idea how corrupt and regulated that side of the business is? Even generic drug prices are artificially manipulated by the original IP owners. The amount of monopolistic laws in pharma driven by lobbying, etc are ridiculous...

[ Parent | on HN ]